The TGF-β Pathway as an Emerging Target for Chagas Disease Therapy

被引：43

作者：

Araujo-Jorge, T. C. ^{[1
]}

Waghabi, M. C. ^{[2
]}

Bailly, S. ^{[3
,4
,5
]}

Feige, J-J ^{[3
,4
,5
]}

机构：

[1] Inst Oswaldo Cruz, Lab Inovacoes Terapias Ensino & Bioprod, BR-20001 Rio De Janeiro, Brazil

[2] Inst Oswaldo Cruz, Lab Genom Func & Bioinformat, BR-20001 Rio De Janeiro, Brazil

[3] INSERM, U1036, Grenoble, France

[4] Inst Rech Technol & Sci Vivant, Commissariat Energie Atom & Energies Alternat, Grenoble, France

[5] Univ Grenoble 1, Grenoble, France

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 92卷 / 05期

关键词：

GROWTH-FACTOR-BETA; TRYPANOSOMA-CRUZI INFECTION; HEART-DISEASE; TRANSFORMING GROWTH-FACTOR-BETA-1; CARDIAC MYOCYTES; GAP-JUNCTIONS; PIVOTAL ROLE; FIBROSIS; INHIBITOR; EXPRESSION;

D O I：

10.1038/clpt.2012.102

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Transforming growth factor-beta (TGF-beta) influences the development of myocardiopathy in Chagas disease through regulation of (i) parasite invasion of heart cells, (ii) an intracellular parasite cycle, (iii) inflammation and immune response, (iv) heart fibrosis and remodeling, and (v) gap junction modulation and heart conduction. In this review, we discuss the rationale for developing TGF-beta signaling-interfering therapies as adjuvant approaches for the management of the cardiac alterations of Chagas disease-affected patients.

引用

收藏

页码：613 / 621

页数：9

相关论文

共 75 条

[1]

Gap Junctions and Chagas Disease [J].

Adesse, Daniel ;

Goldenberg, Regina Coeli ;

Fortes, Fabio S. ;

Jasmin ;

Iacobas, Dumitru A. ;

Iacobas, Sanda ;

Campos de Carvalho, Antonio Carlos ;

Meirelles, Maria de Narareth ;

Huang, Huan ;

Soares, Milena B. ;

Tanowitz, Herbert B. ;

Garzoni, Luciana Ribeiro ;

Spray, David C. .

ADVANCES IN PARASITOLOGY, VOL 76: CHAGAS DISEASE, PT B, 2011, 76 :63-81

[2]

Amiodarone Inhibits Trypanosoma cruzi Infection and Promotes Cardiac Cell Recovery with Gap Junction and Cytoskeleton Reassembly In Vitro [J].

Adesse, Daniel ;

Azzam, Eduardo Meirelles ;

Meirelles, Maria de Nazareth L. ;

Urbina, Julio A. ;

Garzoni, Luciana R. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (01) :203-210

[3]

Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors [J].

Anderton, Mark J. ;

Mellor, Howard R. ;

Bell, Alex ;

Sadler, Claire ;

Pass, Martin ;

Powell, Steve ;

Steele, Samantha J. ;

Roberts, Ruth. R. A. ;

Heier, Annabelle .

TOXICOLOGIC PATHOLOGY, 2011, 39 (06) :916-924

[4]

Immunomodulatory and anti-fibrotic effects of ganglioside therapy on the cardiac chronic form of experimental Trypanosoma cruzi infection [J].

Andrea Cutrullis, Romina ;

Javier Poklepovich, Tomas ;

Postan, Miriam ;

Leon Freilij, Hector ;

Beatriz Petray, Patricia .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (08) :1024-1031

[5]

Pivotal role for TGF-β in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy [J].

Araujo-Jorge, Tania C. ;

Waghabi, Mariana C. ;

Soeiro, Maria de Nazar C. ;

Keramidas, Michelle ;

Bailly, Sabine ;

Feige, Jean-Jacques .

CYTOKINE & GROWTH FACTOR REVIEWS, 2008, 19 (5-6) :405-413

[6]

Implication of transforming growth factor-β1 in chagas disease myocardiopathy [J].

Araújo-Jorge, TC ;

Waghabi, MC ;

Hasslocher-Moreno, AM ;

Xavier, SS ;

Higuchi, MD ;

Keramidas, M ;

Bailly, S ;

Feige, JJ .

JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (12) :1823-1828

[7]

Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole [J].

Benaim, G ;

Sanders, JM ;

Garcia-Marchán, Y ;

Colina, C ;

Lira, R ;

Caldera, AR ;

Payares, G ;

Sanoja, C ;

Burgos, JM ;

Leon-Rossell, A ;

Concepcion, JL ;

Schijman, AG ;

Levin, M ;

Oldfield, E ;

Urbina, JA .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (03) :892-899

[8]

Antitrypanosomal Therapy for Chronic Chagas' Disease [J].

Bern, Caryn .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2527-2534

[9]

TGF-β signaling in fibrosis [J].

Biernacka, Anna ;

Dobaczewski, Marcin ;

Frangogiannis, Nikolaos G. .

GROWTH FACTORS, 2011, 29 (05) :196-202

[10]

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study [J].

Bogdahn, U. ;

Hau, P. ;

Stockhammer, G. ;

Venkataramana, N. K. ;

Mahapatra, A. K. ;

Suri, A. ;

Balasubramaniam, A. ;

Nair, S. ;

Oliushine, V. ;

Parfenov, V. ;

Poverennova, I. ;

Zaaroor, M. ;

Jachimczak, P. ;

Ludwig, S. ;

Schmaus, S. ;

Heinrichs, H. ;

Schlingensiepen, K-H .

NEURO-ONCOLOGY, 2011, 13 (01) :132-142

← 1 2 3 4 5 6 7 8 →